Adalimumab/etanercept/infliximabMalignant melanoma: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2009年 / 1276卷 / 1期

关键词：

Melanoma; Psoriasis; Infliximab; Etanercept; Adalimumab;

D O I：

10.2165/00128415-200912760-00013

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：5 / 5

相关论文

共 50 条

[41] Adalimumab/etanercept/infliximabMalignancy: 7 case reports
Reactions Weekly, 2015, 1565 (1) : 19 - 19
[42] Adalimumab/etanercept/infliximabPsoriasis: 3 case reports
Reactions Weekly, 2007, 1142 (1) : 7 - 7
[43] Adalimumab/etanercept/infliximabTuberculosis: 6 case reports
Reactions Weekly, 2017, 1670 (1) : 15 - 15
[44] Adalimumab/etanercept/infliximabTuberculosis: 16 case reports
Reactions Weekly, 2016, 1592 (1) : 18 - 18
[45] Adalimumab/etanercept/infliximabPsoriasis: 9 case reports
Reactions Weekly, 2006, 1097-1098 (1) : 6 - 6
[46] Adalimumab/etanercept/infliximabPsoriasis: 8 case reports
Reactions Weekly, 2007, 1146-1147 (1) : 6 - 6
[47] Adalimumab/etanercept/infliximabAsthma: 5 case reports
Reactions Weekly, 2012, 1390 (1) : 6 - 6
[48] Adalimumab/etanercept/infliximabBronchospasm: 7 case reports
Reactions Weekly, 2009, 1272 (1) : 5 - 6
[49] Adalimumab/etanercept/infliximabTuberculosis: 11 case reports
Reactions Weekly, 2021, 1859 (1) : 14 - 14
[50] Adalimumab/etanercept
Reactions Weekly, 2012, 1432 (1) : 6 - 6

← 1 2 3 4 5 →